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Tumor Necrosis Factor– Contributes to
Below-Level Neuropathic Pain after
Spinal Cord Injury
Xiang-min Peng, MD, PhD,1 Zhi-gang Zhou, MD, PhD1 Joseph C. Glorioso, PhD,2 David J. Fink, MD,1
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Objective: Our objective was to elucidate the mechanisms responsible for below-level pain after partial spinal cord injury (SCI).
Methods: We used lateral hemisection to model central neuropathic pain and herpes simplex viral (HSV) vector–mediated
transfer of the cleaved soluble receptor for tumor necrosis factor– (TNF-) to evaluate the role of TNF- in the pathogenesis
of below-level pain.
Results: We found activation of microglia and increased expression of TNF- below the level of the lesion in the lumbar spinal
cord after T13 lateral hemisection that correlated with emergence of mechanical allodynia in the hind limbs of rats. Lumbar
TNF- had an apparent molecular weight of 27kDa, consistent with the full-length transmembrane form of the protein
(mTNF-). Expression of the p55 TNF soluble receptor (sTNFRs) by HSV-mediated gene transfer resulted in reduced pain
behavior and a decreased number of ED1-positive cells, as well as decreased phosphorylation of the p38 MAP kinase (p-p38) and
diminished expression of mTNF- in the dorsal horn.
Interpretation: These results suggest that expression of mTNF- after injury is related to development of pain, and that reverse
signaling through mTNF- by sTNFR at that level reduces cellular markers of inflammatory response and pain-related behavior.
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Pain below the level of spinal cord injury (SCI) repre-
sents a clinically important form of central neuropathic
pain that is particularly difficult to treat effectively.1 In
rodent models of peripheral neuropathic pain caused
by chronic constriction injury,2 spinal nerve ligation,3,
4 inflammatory nerve lesion,5 or axotomy,2 nerve in-
jury is accompanied by activation of microglia in the
ipsilateral dorsal horn of the spinal cord. The role of
microglial activation in central neuropathic pain after
SCI has not been established.
Tumor necrosis factor (TNF)–, a prototypical
proinflammatory cytokine, plays a central role in initi-
ating inflammatory reactions of the innate immune
system through induction of the expression and release
of other cytokines,6 among other actions. TNF- is
synthesized as a type II transmembrane protein
(mTNF-) that is cleaved by the TNF-converting en-
zyme, a member of the disintegrin and metalloprotein-
ase family, to release the 17kDa soluble cytokine
sTNF-.7 Both mTNF- and sTNF- are bioactive
although their effects are distinct. sTNF- is a diffus-
ible peptide with a half-life of approximately 30 min-
utes,8 and its activity is neutralized in part by binding
to a cleaved soluble form of the TNF receptor (p55 or
p75 sTNFR). mTNF- mediates bidirectional cell–cell
interactions through binding to the membrane receptor
complex (p55 or P75 TNFR) on neighboring cells;
binding of p55 or p75 sTNFR to mTNFR may pre-
vent such interactions and/or activate intracellular sig-
naling pathways in the mTNF-–expressing cells.9
TNF- appears to play an important role in the de-
velopment of chronic peripheral neuropathic pain. Af-
ter nerve crush, the amount of TNF- detected by im-
munocytochemistry increases in astrocytes and
microglia in the dorsal horn.10 In the chronic constric-
tion injury model of peripheral neuropathic pain, ad-
ministration of neutralizing antibodies against TNF-
or the p55 TNFR reduces thermal hyperalgesia and
mechanical allodynia.11 In the spinal nerve ligation
model of peripheral neuropathic pain, intrathecal ad-
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ministration recombinant p75 sTNFR (etanercept) be-
fore nerve injury reduces mechanical allodynia.12,13 In
this study, we investigated the role of lumbar TNF-
in the development of pain below the level of thoracic
spinal hemisection, using herpes simplex virus (HSV)
vector–mediated release of the soluble cleaved product
of p55 TNFR to modulate mTNF effects.
Materials and Methods
Vectors
Construction of p55 sTNFR-expressing HSV vector,
T0TNFSR, has been described previously.14 This vector con-
tains the coding sequence for amino acids 1 to 211 of the
human p55 sTNFR under regulatory control of the HSV
ICP0 immediate early promoter in the UL41 locus of an
HSV recombinant defective for HSV genes ICP4, ICP22,
and ICP27. Control vector T0Z.1 is defective in the same
genes but contains the Escherichia coli lacZ coding sequence
under the control of ICP0 promoter in the UL41 locus.
Experimental Animals and Surgical Procedures
Female Sprague-Dawley rats weighing 200 to 250gm were
used in all experiments. Housing conditions and experimen-
tal procedures were approved by the University of Michigan
Committee on Use and Care of Animals.
Isoflurane gas was used to anesthetize each rat, and then
the T11-T12 spinal laminae were located by palpating the
last rib. A longitudinal incision was made exposing several
segments, and a laminectomy was performed at T11-T12.
The lumbar enlargement was identified with accompanying
dorsal vessels, and the spinal cord was hemisected at T13
using a scalpel blade. Extra care was taken not to damage the
major dorsal vessels or vascular branches. A tuberculin sy-
ringe with a 28-gauge needle was placed dorsoventrally at the
midline of the cord and pulled laterally to ensure that he-
misection was complete. Muscle and fascia were sutured
closed and the skin closed with autoclips. After surgery, all
animals were maintained under preoperative conditions and
were eating and drinking within 3 hours after surgery. Lo-
comotor function was examined and recorded using the BBB
Locomotor Rating Scale15 to ensure that motor recovery of
the limb ipsilateral to the hemisection was sufficient to allow
somatosensory behavioral testing. Animals meeting behav-
ioral criteria then were inoculated in the plantar surface of
both hind paws with 30l of vector containing 1.5  107
plaque-forming units of T0TNFSR or T0Z.1.
Behavioral Analyses
Behavioral testing for mechanical allodynia was performed
during the day portion of the circadian cycle (8:00 AM to
4:00 PM). Mechanical allodynia was assessed by measuring
the threshold of paw-withdrawal response to mechanical
stimuli using an electronic pressure algometer (Somedic
Sales, Horby, Sweden).16 Rats were placed inside acrylic
cages turned upside down on top of a wire grid allowing
access to the paws and were left to acclimate for a period of
at least 30 minutes, after which the probe of the electronic
pressure algometer was applied to the midplantar surface of
the left and right hind paws. A brisk paw withdrawal after
probe application was regarded as a positive response, and
the force was recorded automatically by the device.
Cell Culture
Dorsal root ganglia (DRG) from 17-day-old rat embryos
were treated with 0.25% trypsin-EDTA (Gibco-BRL, Carls-
bad, CA) for 45 minutes at 37°C, dissociated and plated on
poly-D-lysine–coated coverslips at 1.5  105 cells per well in
a 24-well plate with 500l of defined Neurobasal Media
containing B27, Glutamax I, Albumax I, and penicillin/
streptomycin according to manufacturer’s recommendation
(Gibco-BRL) and supplemented with 100ng/ml of 7.0S
nerve growth factor (Sigma-Aldrich, St. Louis, MO). After
17 days in culture, the cells were transfected with either
T0TNFSR or T0Z.1 at a multiplicity of infection (MOI) of
1 for 2 hours. Fresh medium was replaced and collected 48
hours later for determination of sTNFR by enzyme-linked
immunosorbent assay (ELISA) and Western blot. DRG neu-
rons were also examined for expression of sTNFR protein by
immunocytochemistry and Western blot.
Enzyme-Linked Immunosorbent Assay
The amount of p55 sTNFR released from the transduced
cells was determined using a commercial p55 sTNFR ELISA
kit (TNFR1; R&D Systems, Minneapolis, MN).
Western Blot
The dorsal quadrant was dissected from L4-L6 spinal cord
and homogenized in lysis buffer containing 50mM Tris,
10mM NaCl, 1% NP40, 0.02% NaAzide, and protease in-
hibitor cocktail (Sigma-Aldrich) at pH 7.4. Cultured DRG
cells were collected in similar lysis buffer after being dis-
lodged from culture plates with a cell scraper. Cell lysate and
tissue homogenates were sonicated and then centrifuged at
15,000g for 10 minutes at 4°C. Medium from DRG cell
cultures was centrifuged at 1,000g for 10 minutes at 4°C.
Ammonium sulfate was added to the supernatant to 35%
saturation and centrifuged at 10,000g for 15 minutes at 4°C,
and the pellet was collected for analysis.
Protein concentration in tissue homogenates and cell ly-
sates was determined using the BCA assay (Pierce Biotech-
nology, Rockford, IL) and spectrophotometry (AD340;
Beckman Coulter, Fullerton, CA).
Aliquots containing 20g of protein were dissolved in
Laemmli buffer and boiled at 95°C for 5 minutes, and the
proteins separated by 12% Tris-Glycine SDS-PAGE (BioRad
Laboratories, Hercules, CA) and transferred to nitrocellulose
membranes. Prestained protein standards (RPN800; Amer-
sham Biosciences, Piscataway, NJ) were used to determine
relative molecular weights of proteins. Immunoblots were
blocked and incubated with primary antibodies at 4°C. Pri-
mary antibodies included an antibody against the p55 sT-
NFR (anti-TNF R1, 1:500; Santa Cruz Biotechnology,
Santa Cruz, CA; directed against amino acids 30–301 of the
receptor), anti–TNF- (1:1000; R&D Systems), and anti-
phospho-p38 and anti-p38 (1:500; Cell Signaling Technol-
ogy, Beverly, MA). Peroxidase-coupled secondary antibodies
(Calbiochem, La Jolla, CA) were used for amplification. Pro-
tein bands were visualized using X-OMAT AR film (Kodak,
Rochester, NY) after chemiluminescence (DuPont NEN,
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Boston, MA). The membranes were stripped and reprobed
with mouse anti–-actin (1:5000; Santa Cruz Biotechnol-
ogy) as a loading control. The intensity of each band was
determined by quantitative densitometry using a PC-based
image analysis system (ChemiDoc XRS System, BioRad Lab-
oratories).
Immunochemistry
Rats were perfused transcardially with 0.9% NaCl followed
by freshly made 4% paraformaldehyde in 0.1M phosphate
buffer (pH 7.4). The DRG, L4-L6 segment of spinal cord,
and attached roots were removed, postfixed in the same so-
lution for 8 hours, and cryoprotected with 30% sucrose in
0.1M phosphate buffer for 2 days at 4°C. Cryostat sections
(15m) of DRG were thaw-mounted onto cold Superfrost
microscope slides (Fisher Scientific, Pittsburgh, PA), blocked
with 5% normal goat serum in PBS-T, and incubated with
rabbit anti-TNF R1 (1:200; Santa Cruz Biotechnology) over-
night at 4°C followed by fluorescent anti-rabbit IgG Alexa
Fluor 594 (1:2,000; Molecular Probes, Eugene, OR) for 1
hour at room temperature. Floating sections (35m) of spi-
nal cord were blocked and incubated overnight at 4°C with
rabbit polyclonal anti-phospho p38 (1:200; Cell Signaling
Technology), mouse monoclonal anti-OX42 (1:200; Chemi-
con International, Temecula, CA), mouse anti-ED1 (1:200,
Chemicon International), mouse anti-NeuN (1:500; Chemi-
con International), or mouse anti-GFAP (1:500; Sigma-
Aldrich) followed by fluorescent anti–rabbit IgG Alexa Fluor
594 or fluorescent anti–mouse IgG Alexa Fluor 488
(1:2,000; Molecular Probes) for 1 hour at room temperature.
All sections were mounted in water-based Fluoromount-G
(Electron Microscopy Sciences, Hatfield, PA), and the fluo-
rescent images were captured using a Nikon Eclipse E1000
microscope.
The expression of T0TNFSR in DRG neurons in vitro
was determined by immunocytochemistry. Forty-eight hours
after transfection, the cells were fixed, blocked, and probed
with anti-sTNFR1 (1:500; Santa Cruz Biotechnology) or
anti-Tuj1 (1:8000; Covance Research Products, Berkeley,
CA) overnight. The secondary antibodies utilized were fluo-
rescent anti-rabbit IgG Alexa Fluor 594 or anti-mouse IgG
Alexa Fluor 488 (1:2,000; Molecular Probes).
Data Analysis
Statistical significance of the difference between vector-
treated and control animals was determined by one-way anal-
ysis of variance with post hoc comparisons where appropri-
ate. Parametric statistics, using the general linear model for
repeated measures, were used to identify significant effects of
treatment condition on the behavioral measure of neuro-
pathic pain. The results were examined using the software
package SPSS 12.0 for Windows (SPSS, Chicago, IL). Data
are expressed as mean  standard error of mean (SEM), with
p value less than 0.05 considered significant.
Results
Lateral hemisection at T13 resulted in striking inflam-
matory changes in the lumbar spinal cord below the
level of the cord lesion. The number of ramified mi-
croglia in the lumbar spinal cord, detected by OX42
immunoreactivity, was markedly increased compared
with control spinal cord (Fig 1A, B), and there was an
associated increase in the amount of phosphorylated
p38 MAP kinase (p-p38) localized predominantly in
the nucleus and cytoplasm of the activated microglia
(see Fig 1C, D, F). Neurons stained with NeuN and
astrocytes stained with GFAP showed no p-p38 immu-
noreactivity (data not shown). In addition, infiltrating
ED1-positive cells were found in the white matter
tracts including the dorsal columns and in the dorsal
horn bilaterally in the lumbar cord below the level of
the lesion (see Fig 1G, H). Although ED1 may label
both macrophages and microglia, these cells had the
rounded shape characteristic of macrophages, and the
OX42-positive microglia in the gray matter did not co-
label with ED1 in these sections.
In the same region of the lumbar cord, there was a
substantial increase in immunoreactive TNF- that
persisted 3 days to 2 weeks after T13 hemisection (Fig
2). The immunoreactive peptide had an apparent mo-
lecular weight of 27kDa, consistent with the full-length
membrane form of TNF- (mTNF-). We were un-
able to detect the presence of soluble cleaved TNF-
(sTNF-, 17kDa) in a cytosolic fraction prepared from
lumbar spinal cord using either ELISA or Western blot
at those time points. Our inability to detect sTNF-
was not a technical artefact, because in other studies we
were able to detect a transient increase in sTNF- by
ELISA at the site of blunt trauma to the spinal cord
(data not shown).
To examine the role of TNF- in the inflammatory
process, we used a nonreplicating HSV gene transfer
vector (T0TNFSR) to express sTNFR (see supplemen-
tary materials; Fig 1A). DRG neurons in culture trans-
duced with T0TNFSR at an MOI of 1 expressed sT-
NFR detected by immunocytochemistry and Western
blot (see supplementary materials; Fig 1B, C), and re-
leased sTNFR into the medium as detected by Western
blot and ELISA (see supplementary materials; Fig 1D,
E). One week after subcutaneous inoculation of
T0TNFSR into the plantar surface of the hind paws,
sTNFR could be detected in neurons of the L4-L6
DRG ipsilateral to the inoculation site using immuno-
cytochemistry and Western blot (see supplementary
materials; Fig 2A, B). Using Western blot, we found
that the ipsilateral dorsal horn of spinal cord contain-
ing the nerve terminals of transduced cells showed sub-
stantial amounts of sTNFR in T0TNFSR-inoculated
animals but not in control or TOZ.1-inoculated ani-
mals (see supplementary materials; Fig 2C).
Animals with pain below the level of lateral hemisec-
tion developed mechanical allodynia, as measured by
response to von Frey filaments (Fig 3). Subcutaneous
inoculation of vector T0TNFSR into the plantar sur-
face of both hind paws 1 week after hemisection re-
sulted in a significant reduction in pain-related re-
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sponse (see Fig 3). The vector-mediated effect was
present by 1 week after inoculation (2 weeks after in-
jury) and peaked 2 to 3 weeks after inoculation (see
Fig 3).
In conjunction with the reduction in mechanical hy-
peralgesia, subcutaneous inoculation of T0TNFSR 1
week after T13 hemisection also resulted in a signifi-
cant reduction in mTNF- (Fig 4A, B), p-p38 (see Fig
4 C–E), and the number of ED1-positive cells in the
dorsal column and dorsal horn of the lumbar spinal
cord (Fig 5), similar to levels seen in uninjured ani-
mals.
Discussion
In this study, we report that expression of mTNF- is
increased drastically in the lumbar spinal cord several
segments below the level of a lateral hemisection in-
jury: HSV-mediated expression of p55 sTNFR in
DRG neurons projecting the lumbar spinal cord (1)
reversed the activation of microglial p38; (2) reduced
mTNF- protein; and (3) decreased the number of in-
vading ED1-positive macrophages in the dorsal col-
umns and dorsal horn of lumbar spinal cord below the
level of the lesion, resulting in reduced mechanical al-
Fig 1. Immunocytochemical staining of lumbar spinal cord from control (A, C, E, G) and rats 2 weeks after T13 hemisection (B,
D, F, H) show substantial increases in OX42-positive microglia (A, B), p-p38 (C, D; merged images E, F; scale bar  10m),
and ED1-positive cells in the white matter tracts (dorsal column, arrows) in the lumbar spinal cord (G, H; scale bar  20m).
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lodynia in this model of central neuropathic pain be-
low the level of SCI.
Chronic neuropathic pain represents a major com-
plication of spinal cord injury. The current taxonomy
proposed by the SCI Pain Task Force of the Interna-
tional Association for the Study of Pain recognizes
three types of neuropathic pain after SCI: above-level
pain, at-level pain, and below-level pain.1 Several ani-
mal models have been established that exhibit behav-
ioral manifestations that are interpreted to reflect essen-
tial features for each of the different types of post-SCI
pain.17 This study focused on below-level pain that de-
velops after SCI,1 utilizing the widely accepted lateral
hemisection model of below-level pain in the rat.18
Central immune activation plays an important role
in the development of chronic pathological pain after
damage to the nervous system.19 In rodent models of
peripheral neuropathic pain, partial peripheral nerve
damage results in activation of glia in the spinal
cord.20–22 Treatments that reduce pain also block glial
activation,23 and disruption of spinal glial activation
reduces nocisponsive behaviors.24–26 Activated glia syn-
thesize several potentially algesic substances including
TNF-, interleukin-1, and the prostanoid PGE2.27 In-
trathecal administration of inflammatory cytokines has
a proalgesic effect in normal28 and nerve-injured ani-
mals,29 and inhibition of spinal TNF- activity re-
duces pain behavior in several models.5,24 Transgenic
mice that overexpress TNF- in glia show increased
mechanical allodynia after peripheral nerve damage
compared with control animals.30
Microglial activation caused by peripheral nerve in-
jury results in increased phosphorylation of p38 MAP
kinase in spinal cord.13,31 A role for TNF- is sug-
gested by the observations that direct injection of
TNF- into peripheral nerve induces thermal hyperal-
gesia and mechanical allodynia, and damaged nerves
are hypersensitive to the proalgesic effects of TNF-
.12,32,33 Interference with TNF- effects by intrathe-
cal administration of the soluble form of p75 TNFR
(etanercept) blocks the increase of p-p38 in spinal cord
after spinal nerve ligation13 but only if the antibody is
administered before the injury. Intrathecal administra-
tion of neutralizing antibodies against the p55 TNFR
(but not antibodies against the p75 TNFR) reduce
pain in the chronic constriction injury model of pe-
ripheral neuropathic pain.11
We found substantial amounts of full-length
mTNF-, identified by its molecular weight on West-
ern blot, in the lumbar spinal cord at a time when we
were unable to detect soluble cleaved TNF- in a su-
pernatant from the same sample either by ELISA or
Western blot. Our inability to detect soluble TNF-
below the level of hemisection was not the result of a
technical problem, because we were able to detect sol-
uble TNF- transiently at the site of blunt trauma to
Fig 3. T0TNFSR reduces mechanical allodynia. T13 hemisec-
tion resulted in a decrease in paw withdrawal threshold (me-
chanical allodynia), which persisted for 5 weeks as shown in
T0Z.1-treated animals (triangles). Animals inoculated with
T0TNFSR showed an increase in threshold value (circles)
both ipsilateral (A) and contralateral (B) to the hemisection. p
 0.01 by repeated measures; N  6 animals per group.
Fig 2. mTNF- in lumbar spinal cord increased 3 days to 2
weeks after T13 spinal hemisection. Immunoreactive TNF-
had an apparent molecular weight of 27kDa, consistent with
full-length mTNF- compared with sTNF (arrow, recombi-
nant sTNF-) that has an apparent molecular weight of
17kDa.
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the spinal cord in the first few hours after injury using
the same methods.
In the immune system, an emerging body of litera-
ture suggests that “reverse” signaling through mTNF
may serve to regulate the immune response.9 Stimula-
tion of mTNF in monocytes confers resistance to bac-
terial endotoxin to reduce the release of proinflamma-
tory cytokines34 and resistance to the influence of
inflammatory agents, while in other settings reverse sig-
naling through mTNF may induce apoptosis in in-
flammatory cells.35 In monocytes, p55 sTNFR is a po-
tent activator of reverse signaling through mTNF-
,36,37 and it seems likely that release of sTNFR from
the terminals of transduced DRG neurons reduces
mTNF- expression in microglia and macrophages
through a reverse signaling mechanism. Although we
cannot exclude the possibility that biologically relevant
but undetectable amounts of soluble TNF- were
present, this would be a less likely mechanism to ac-
count for the observed effects of sTNFR.
The studies reported do not establish that block of
p38 phosphorylation is required to downregulate
Fig 4. T13 hemisection resulted in an increased in mTNF- in lumbar spinal cord. Animals inoculated with T0TNFSR, but not
animals inoculated with T0Z.1, showed a reduction in TNF- 1 week after injection, 2 weeks after hemisection. (A) Western blot.
(B) Relative optical density  area expressed to relative control. Mean  SEM. N  5, (asterisks) p  0.05. The level of p-p38
in L4-L6 lumbar spinal cord also increased after T13 hemisection, but this increase was blocked in animals transduced with
T0TNFSR. (C) Western blot. (D) Level of p-p38 was determined by densitometry, normalized to total p38, and expressed as
percentage-change relative to control. Mean  SEM, N  5, (double asterisks) p  0.01. (E) Anti–p-p38 immunostained section
showed a marked increase in cells of the dorsal horn that were reduced in animals inoculated with T0TNFSR. Scale bar 
40m.
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mTNF expression, but expression of proinflammatory
cytokines including TNF, IL-1, IL-6, and IL-8 as well
as the enzymes cyclooxygenase II, collagenase, and
iNOS occur downstream of p38 activation,38 and this
expression can be blocked by p38 inhibitors.39 In ad-
dition, TNF- acting through the p38 MAPK path-
way is a potent activator of NF-kB which in turn is
an inducer of TNF- expression, a positive feedback
loop that contributes to the development of chronic
inflammatory conditions and possibly chronic pain
states.40,41 Pretreatment prior to onset of pain is re-
quired for etanercept (p75 sTNFR) to provide an an-
tiallodynic effect in the spinal nerve ligation model of
peripheral neuropathic pain.13,42 However, we found
that transgene-mediated expression of the p55 form
of sTNFR from the vector 1 week after SCI and after
a time of established pain behavior was nonetheless
effective in reducing the phosphorylation of p38
MAP kinase and reducing nocisponsive behavior.
What accounts for the increase in mTNF- levels at
L5 after a lateral hemisection at T13? SCI induces a
rapid upregulation in expression of TNF- and TNFR
within hours in the region of injury that resolves rap-
idly43,44 and may play a role in cell death in that
area.45, 46 After dorsal hemisection, remote activation
of several chemokines including monocyte chemoat-
tractant protein-1 and macrophage inflammatory pro-
tein 1 has been reported, presumably related to distal
fiber degeneration after injury.47
In summary, T13 hemisection resulted in invasion
of inflammatory cells and activation of microglia in the
lumbar spinal cord with concurrent expression of
mTNF below the level of the spinal cord lesion.
Downregulation of mTNF through reverse signaling
by sTNFR through mTNF correlated with a reduc-
tion in p38 MAP kinase and mechanical allodynia in
this model.
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